Key facts
- Notable investors include Ventura BioMed Investors.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for PHiNE Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for PHiNE Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PHiNE Bio
Developer of precision gene delivery technology designed for ex vivo and in vivo applications of genetic material. The company uses proprietary protein engineering and artificial intelligence to enable highly efficient, safe, and cost-effective delivery of genetic material, enabling healthcare and biotechnology companies advance in cell and gene therapy and address major industry challenges.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2025
- Website
- phinebio.com/
- Ownership
- Privately Held (backing)
PHiNE Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PHiNE Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PHiNE Bio in its N-PORT filings yet. We sweep new filings monthly.